Provided by Tiger Trade Technology Pte. Ltd.

Monte Rosa Therapeutics

18.66
+2.2113.43%
Pre-market: 19.160.5000+2.68%09:24 EST
Volume:3.07M
Turnover:56.31M
Market Cap:1.22B
PE:73.92
High:18.98
Open:17.19
Low:17.19
Close:16.45
52wk High:18.98
52wk Low:3.50
Shares:65.12M
Float Shares:24.48M
Volume Ratio:4.24
T/O Rate:12.53%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.2524
EPS(LYR):-0.9836
ROE:9.28%
ROA:1.37%
PB:4.94
PE(LYR):-18.97

Loading ...

Why Is Monte Rosa Stock Trading Higher Today?

Benzinga_recent_news
·
18 hours ago

Top Midday Gainers

MT Newswires Live
·
20 hours ago

Wedbush Adjusts Monte Rosa Therapeutics Price Target to $26 From $19, Maintains Outperform Rating

MT Newswires Live
·
22 hours ago

Wells Fargo Upgrades Monte Rosa Therapeutics to Overweight From Equalweight, Adjusts Price Target to $22 From $13

MT Newswires Live
·
Yesterday

Monte Rosa Therapeutics Showcases Pipeline Advances and Strategic Partnerships in Targeted Protein Degradation

Reuters
·
Yesterday

BRIEF-Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide

Reuters
·
Yesterday

Monte Rosa Therapeutics Announces Compelling Clinical Activity of Mrt-2359 in Combination With Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients With Androgen Receptor Mutations

THOMSON REUTERS
·
Yesterday

Monte Rosa Therapeutics Announces Updated Phase 1/2 Study Results for MRT-2359 in mCRPC

Reuters
·
Yesterday

Monte Rosa Therapeutics Announces Phase 1 Study of NEK7 Degrader MRT-8102 for Cardiovascular Diseases

Reuters
·
Nov 10

Monte Rosa Therapeutics presents preclinical data on MRT-8102

TIPRANKS
·
Nov 10

Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases

GlobeNewswire
·
Nov 09

Monte Rosa Therapeutics Is Maintained at Equal-Weight by Wells Fargo

Dow Jones
·
Nov 08

Monte Rosa Therapeutics Reports Strong Revenue Growth

TIPRANKS
·
Nov 07

Monte Rosa Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
Nov 07

Monte Rosa Therapeutics: Strategic Partnerships and Growth Potential Justify Buy Rating

TIPRANKS
·
Nov 07

Monte Rosa Therapeutics Showcases Pipeline Advances and Strategic Partnerships in Protein Degradation Therapies

Reuters
·
Nov 06

Monte Rosa Therapeutics Q3 Sales $12.768M Beat $5.420M Estimate

Benzinga
·
Nov 06

Monte Rosa Q3 net loss widens, but revenue increases on Novartis payment

Reuters
·
Nov 06

BRIEF-Monte Rosa Therapeutics Q3 Operating Income USD -32.975 Million

Reuters
·
Nov 06

Press Release: Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business Updates

Dow Jones
·
Nov 06